2025-522512-16-00招募中1 期
Phase 1 trial of valemetostat and darolutamide in mCRPC
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 13
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Trial Office
Scientific
Daiichi Sankyo Inc.
研究点 (7)
Loading locations...
相似试验
招募中
3 期
An open study for participants who have been on darolutamide treatment in any other Bayer studyCancer2022-502084-38-00Bayer Consumer Care AG, Bayer AG258
招募中
3 期
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imaging2023-509787-15-00Unicancer450
招募中
2 期
An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors.2024-519788-16-00Institut Gustave Roussy600
招募中
2 期
SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial2024-512132-29-00Swiss Group for Clinical Cancer Research100
招募中
1 期
Phase I trial with 177Lu-DOTA-TATE and olaparib in somatostatin receptor positive tumours2024-512463-31-00Vaestra Goetalandsregionen18